In a laboratory in Logan, Utah, a membrane made from hagfish proteins is doing something that human eyes can't: aging 60 years in just four weeks. The breakthrough belongs to Elizabeth Vargis and her team at Utah State University, who have cracked one of medicine's toughest puzzles—how to replicate age-related macular degeneration in a controlled setting, opening a path toward treatments that could prevent blindness in millions of people worldwide.
Age-related macular degeneration, or AMD, is the leading cause of blindness in older adults, yet it has remained stubbornly difficult to study. The disease develops when retinal pigment epithelium cells—the caretakers of the light-sensitive rods and cones in your eye—become strained and less effective due to aging, genetics, and environmental factors. For decades, researchers have struggled to recreate this slow decay in the lab. Now they have.
Working with doctoral student Dillon Weatherston and Associate Professor Justin Jones, Vargis discovered that a tunable membrane derived from hagfish proteins could mimic the conditions of a naturally aging eye. When the team grew retinal pigment epithelium cells from pig eyes on this synthetic membrane, they watched as the cells behaved just like those in an aging human eye—producing fatty deposits and protein markers that signal early-stage AMD. The findings, published in GeroScience, a leading journal on aging and age-related diseases, represent a watershed moment for understanding and treating a condition that affects millions.
Current AMD treatments are frustratingly limited. Vitamin supplements can reduce the risk of developing the disease, but they lose effectiveness once vision loss begins. Injectable drugs work only in the late stages, requiring monthly eyeball injections. "It's 2026, and I feel like we should have something better," Vargis said—a sentiment that captures both the urgency and the gap between current options and what's possible.
What makes this breakthrough especially significant is that it's not just about AMD. Vargis emphasized that the real power lies in having created a model system that accurately mimics human aging at the cellular level. Jones noted that by imitating human physiology in the lab, discoveries made with this model can transfer to other age-related diseases, including Alzheimer's. The team can now test potential drugs against the system to evaluate whether they might treat or cure AMD—a capability that didn't exist before.
The research has already attracted serious attention. The USU team has filed a nonprovisional patent for the technology and founded MyxTek Bio, a spinout company guided by Jones and Vargis, which has been recommended for National Science Foundation funding to develop and commercialize the AMD model system. This infrastructure suggests the researchers are serious about moving from the lab bench to real-world applications.
Jones summed up the promise in straightforward terms: "The power of this research is that we developed a model system that we can test drugs against to help treat and cure AMD." As the team works to make the technology more widely available to the research community, they remain focused on their ultimate goal. "We are incredibly hopeful that through our efforts we can successfully transition this model system to help find a cure or more effective treatment for AMD," Jones said. For the millions of people living with vision loss, that hope is worth more than any current injection.